3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
Nevin John,
Nathaniel Lizak,
Tomas Kalincik,
Mark Slee,
Suzanne Hodgkinson,
Helmut Butzkueven,
Jeanette Lechner-Scott,
Anneke Van Der Walt,
Izanne Roos,
Katherine Buzzard,
Olga Skibina,
Sifat Sharmin
Affiliations
Nevin John
Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, London, UK
Nathaniel Lizak
1 NeuroCure Clinical Research Center, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
Tomas Kalincik
CORe, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Mark Slee
9Liverpool Hospital, Sydney, NSW, Australia
Suzanne Hodgkinson
9Liverpool Hospital, Liverpool, NSW, Australia
Helmut Butzkueven
Clinical Neurosciences, Alfred Health, Melbourne, Victoria, Australia
Jeanette Lechner-Scott
The University of Newcastle, Newcastle, New South Wales, Australia
Anneke Van Der Walt
3Department of Neurosciences, Monash University, Prahran, VIC, Australia
Izanne Roos
CORe, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Katherine Buzzard
4 Eastern Health, Box Hill, Victoria, Australia
Olga Skibina
Clinical Neurosciences, Alfred Health, Melbourne, Victoria, Australia
Sifat Sharmin
CORe, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
